tbuckley/cabot-search huggingface dataset:
Reporting Both Unadjusted and Adjusted Estimates Is Essential to the Interpretation of Randomized Clinical Trial Results—Reply
Authors: Matthew N. Cooper, Andrew J. O. Whitehouse, Wesley Billingham
Journal: JAMA Pediatrics (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Erratum
Journal: BMJ (1892)

paroxysm of the fever is expected, then increased again to the 3-grain ones, and continued as described to next paroxysm.During the premonitory or cold stage of West Indian fevers we ad- minister quinine with pure capsicum properly diluted, and it often lessens or entirely cuts off the succeeding hot stage; we call it the " anticipating draught."It is not however all malarial fevers that have a decided cold stage, and this, as described by " Daers," is a form I have frequently noticed. NOTES. LETTERS, Etc.DURIN-G 1891 no fewer than 2,951 petitions, bearing 90,661 signatures, praying for the repeal of the existing vaccination law, were addressed to the Germani Reichstag.
Identification of lipid-rich aortic atherosclerotic plaques in living rabbits with a near infrared spectroscopy catheter Pedro R. Moreno, S. Eric Ryan, David Hopkins, K-Raman Purushothaman, William E. Charash, William O'Connor, James E. Muller. University of Kentucky, Lexington, KY, InfraReDx, Cambridge, MA
Journal: Journal of the American College of Cardiology (2001)
Time course of apoptosis and proliferation in the intima and media following experimental brachytherapy with the liquid beta-emitter rhenium-188 Joachim Kamenz, Markus Wohlfrom, Patrick Stiller, Christina Lenz, Christoph Sadowski, Beate Hess, Martin Hoeher, Joerg Kotzerke, Hartmut Hanke. University of Ulm Department of Cardiology, Ulm, Germany, University of Ulm Department of Nuclear Medicine, Ulm, Germany
Journal: Journal of the American College of Cardiology (2001)
1063-52 Lack of efficacy of clopidogrel pretreatment in the prevention of myocardial damage after elective stent implantation
Authors: Dirk J van der Heijden, Iris C Westendorp, Robert K Riezebos, Ferdinand Kiemeneij, Ton Slagboom, Ron L van der Wieken, Gert-Jan Laarman
Journal: Journal of the American College of Cardiology (2004)
Endocrinology
Journal: JAMA (2002)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
CD4+ T cells from COVID-19 mRNA vaccine recipients recognize a conserved epitope present in diverse coronaviruses
Authors: Bezawit A. Woldemeskel, Arbor G. Dykema, Caroline C. Garliss, Saphira Cherfils, Kellie N. Smith, Joel N. Blankson
Journal: Journal of Clinical Investigation (2022)

Recent studies have shown that vaccinated individuals harbor T cells that can cross-recognize SARS-CoV-2 and endemic human common cold coronaviruses. However, it is still unknown whether CD4+ T cells from vaccinated individuals recognize peptides from bat coronaviruses that may have the potential of causing future pandemics. In this study, we identified a SARS-CoV-2 spike protein epitope (S815-827) that is conserved in coronaviruses from different genera and subgenera, including SARS-CoV, MERS-CoV, multiple bat coronaviruses, and a feline coronavirus. Our results showed that S815-827 was recognized by 42% of vaccinated participants in our study who received the Pfizer-BioNTech (BNT162b2) or Moderna (mRNA-1273) COVID-19 vaccines. Using T cell expansion and T cell receptor sequencing assays, we demonstrated that S815-827-reactive CD4+ T cells from the majority of responders cross-recognized homologous peptides from at least 6 other diverse coronaviruses. Our results support the hypothesis that the current mRNA vaccines elicit T cell responses that can cross-recognize bat coronaviruses and thus might induce some protection against potential zoonotic outbreaks. Furthermore, our data provide important insights that inform the development of T cell-based pan-coronavirus vaccine strategies.
Temporal trends in initiation of mineralocorticoid receptor antagonists and risk of subsequent withdrawal in patients with heart failure: a nationwide study in <scp>Denmark</scp> from 2003–2017
Authors: Deewa Zahir, Anders Bonde, Christian Madelaire, Morten Malmborg, Jawad H. Butt, Emil Fosbol, Gunnar Gislason, Christian Torp‐Pedersen, Charlotte Andersson, Patrick Rossignol, John J.V. McMurray, Lars Kober, Morten Schou
Journal: European Journal of Heart Failure (2021)
QT dispersion in gene-affected members without hypertrophy in familial hypertrophic cardiomyopathy caused by myosin-binding protein C gene mutation Hiroaki Kitaoka, Toru Kubo, Makoto Okawa, Toshikazu Yabe, Takashi Furuno, Yoshinori Doi, Akinori Kimura. Kochi Medical School, Kochi, Japan
Journal: Journal of the American College of Cardiology (2001)
(−)-Epigallocatechin-3-Gallate Prevents Photocarcinogenesis in Mice through Interleukin-12–Dependent DNA Repair
Authors: Syed M. Meeran, Sudheer K. Mantena, Craig A. Elmets, Santosh K. Katiyar
Journal: Cancer Research (2006)

Abstract We have shown previously that topical application of (−)-epigallocatechin-3-gallate (EGCG), the major polyphenol of green tea, prevents photocarcinogenesis in mice. EGCG prevents UVB-induced immunosuppression by inducing interleukin-12 (IL-12). As immunosuppression is a risk factor for photocarcinogenesis, we investigated the possibility that EGCG also prevents UVB-induced photocarcinogenesis through an IL-12–dependent DNA repair mechanism. To investigate this possibility, we determined the effects of EGCG on photocarcinogenesis in IL-12 knockout (KO) mice using the formation of cyclobutane pyrimidine dimers (CPD) as an indicator of the extent of UVB-induced DNA damage. Topical application of EGCG (1 mg/cm2 skin) prevented photocarcinogenesis in wild-type (C3H/HeN) mice in terms of tumor incidence and tumor multiplicity but did not prevent photocarcinogenesis in IL-12 KO mice. UVB-induced DNA damage, as determined by the formation of CPDs and the number of sunburn cells, was resolved more rapidly in the skin of wild-type mice treated with EGCG than untreated control mice. In contrast, the extent of UVB-induced DNA damage and the numbers of sunburn cells were not significantly different in the EGCG-treated IL-12 KO mice and untreated control mice. In addition, treatment of XPA-proficient human fibroblast cells with EGCG promoted repair of UVB-induced CPDs in a dose-dependent manner but not in an XPA-deficient cells, indicating that the nucleotide excision repair mechanism is involved in EGCG-mediated DNA repair. Taken together, these results indicate for the first time that EGCG can prevent photocarcinogenesis through an EGCG-induced IL-12–dependent DNA repair mechanism. (Cancer Res 2006; 66(10): 5512-20)
JHEP at a glance (September 2020)
Authors: Quentin Anstee, Rebecca Darlay, Simon Cockell, Christopher Day, Heather Cordell, Ann Daly, Monika Sarkar, Joshua Grab, Jennifer Dodge, Roxanna Irani, Marcelle Cedars, Norah Terrault, Alexander Stockdale, Benno Kreuels, Marc Henrion, Catherine De Martel, Yvan Hutin, Anna Geretti, Yu Sun, Qing Wang, Yu Zhang, Junqiu Yue, Kun Huang, Ling Zheng
Journal: Journal of Hepatology (2020)
Myocardial doppler velocities during low level exercise echocardiography: Off-line quantitative assessment of myocardial viability early after myocardial infarction Patrizio Lancellotti, Evdokia Petropoulu, Ali R. Bilge, Luc A. Pierard. University hospital cardiology department, Liege, Belgium
Journal: Journal of the American College of Cardiology (2001)
Investigating the prognostic value of TP53 and PIK3CA mutations in metastatic colorectal cancer (mCRC): Applying Structured Query Language (SQL) algorithms to real-world data from a high-volume U.K. tertiary cancer center.
Authors: Caroline Fong, Ali Abdulnabi Mohamed, Geraldo Alves de Paula Neto, Marion Teare, Elli Bourmpaki, Clare Peckitt, David J. Watkins, Sheela Rao, Naureen Starling, Ian Chau, David Cunningham
Journal: Journal of Clinical Oncology (2022)

57 Background: Real world data is a valuable research resource but manual data collection is time consuming and labour intensive. As there is no consensus on the prognostic role of TP53 and PIK3CA mutations in mCRC, we assessed the feasibility of using SQL, a programming language, to derive data from routine electronic clinical notes to investigate the prognostic impact of TP53 and PIK3CA mutations in mCRC. Methods: A cohort of patients (pts) diagnosed with metastatic or recurrent colorectal cancer as per ICD-10 classification from January 2015 to December 2017 and managed at the Royal Marsden Hospital were identified using SQL algorithms developed in-house. Baseline demographics, histopathological and molecular characteristics and death dates were derived from the Electronic Patient Record and extracted in a structured format for statistical analysis. Mutational analysis of TP53 and PIK3CA were performed with standard of care KRAS, NRAS and BRAF testing using next generation sequencing. Overall survival (OS) according to TP53 or PIK3CA mutational status was estimated using the Kaplan-Meier method. Uni- and multivariate Cox regression included KRAS, NRAS, BRAF, sidedness and mismatch repair (MMR) status. Association between TP53 or PIK3CA and MMR status was tested by the Chi squared test. Results: A total of 367 mCRC pts were identified; 10 were excluded due to ineligibility or inadequate data availability. Based on a final dataset of 357 pts, 342 and 354 pts had TP53 and PIK3CA results available. The incidence of TP53 mutations was 75% (n = 257/342) and PIK3CA 16% (n = 55/354). Co-mutations with KRAS, NRAS and BRAF were seen (Table). The overall median follow-up was 42.3 and 42.7 months for TP53 and PIK3CA respectively. There was no difference in OS between TP53 mutant (MT) and wild type (WT) pts (22.0 vs. 22.8 months, p = 0.96) and between PIK3CA MT and WT pts (21.7 vs. 22.4 months, p = 0.49). Right sided and BRAF MT tumours were associated with poorer survival than left sided and BRAF WT tumours when all other factors were constant for TP53 (p&lt;0.001 &amp; p=0.033 respectively) and PIK3CA (both p&lt;0.001) OS on multivariate analysis. MMR deficient tumours were significantly more frequent in TP53 WT compared to TP53 MT tumours (15% vs. 4%, p=0.001) while they were significantly more frequent in PIK3CA MT compared to PIK3CA WT tumours (20% vs. 5%, p &lt; 0.001). Conclusions: Bespoke SQL algorithms enables large-scale data extraction to facilitate research. Based on this dataset, we have shown that TP53 and PIK3CA mutations have no prognostic impact in mCRC. [Table: see text]
FROM WASHINGTON.
Journal: JAMA (1884)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
LEAP-005: A phase 2 multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors—Results from the colorectal cancer cohort.
Authors: Carlos A. Gomez-Roca, Eduardo Yanez, Seock-Ah Im, Eduardo Castanon Alvarez, Hélène Senellart, Mark Doherty, Javier Garcia-Corbacho, Juanita Suzanne Lopez, Bristi Basu, Corinne Maurice-Dror, Sanjeev Singh Gill, Razi Ghori, Peter Kubiak, Fan Jin, Kevin Glen Norwood, Hyun Cheol Cheol Chung
Journal: Journal of Clinical Oncology (2021)

3564 Background: Pembrolizumab (pembro), an anti-PD-1 antibody, is approved for the treatment of patients (pts) with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair (MMR) deficient colorectal cancer, both as first-line treatment and after progression following treatment with fluoropyrimidine, oxaliplatin, and irinotecan. The combination of lenvatinib, a multiple receptor tyrosine kinase inhibitor, and anti-PD-1 treatment showed synergistic antitumor activity in preclinical models. LEAP-005 (NCT03797326) is evaluating the efficacy and safety of lenvatinib plus pembro in pts with previously treated advanced solid tumors. We present findings from the colorectal cancer cohort. Methods: In this nonrandomized, open-label, phase 2 study, adult pts (aged ≥18 y) with histologically/cytologically documented metastatic and/or unresectable colorectal cancer, non–MSI-H/pMMR tumor per local determination, previous treatment with oxaliplatin and irinotecan in separate lines of therapy, measurable disease per RECIST v1.1, ECOG PS of 0‒1, and a tissue sample evaluable for PD-L1 expression were eligible. Pts received lenvatinib 20 mg QD plus pembro 200 mg Q3W for up to 35 cycles of pembro (̃2 y) or until confirmed disease progression, unacceptable toxicity, or withdrawal of consent. Treatment with lenvatinib could continue beyond 2 y in pts with clinical benefit. Primary endpoints were ORR (per RECIST v1.1 by blinded independent central review) and safety. Secondary endpoints included disease control rate (DCR), duration of response (DOR), PFS, and OS. Tumor imaging was performed Q9W from treatment initiation for 54 wks, then Q12W to week 102, and Q24W thereafter. Results: 32 pts with colorectal cancer received treatment with lenvatinib plus pembro (median age, 56 y [range, 36-77]; male, 81%; 3L, 91%); median time from first dose to data cutoff (April 10, 2020) was 10.6 mo (range, 5.9-13.1). ORR was 22% (95% CI, 9–40; table). Grade 3–5 treatment-related AEs occurred in 16 (50%) pts. Treatment-related AEs led to treatment discontinuation in 3 pts (grade 2 ischemic stroke [n = 1], grade 3 increased liver transaminases [n = 1], grade 5 intestinal perforation [n = 1]). Conclusions: In pts with previously treated advanced non–MSI-H/pMMR colorectal cancer, lenvatinib plus pembro demonstrated promising antitumor activity and a manageable safety profile. Enrollment in the colorectal cohort was expanded to 100 pts. Clinical trial information: NCT03797326. [Table: see text]
Outbreak of a Distinct Strain of Penicillinase-Producing Neisseria gonorrhoeae-King County, Washington
Journal: JAMA (1988)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Phiclust: a clusterability measure for single-cell transcriptomics reveals phenotypic subpopulations
Authors: Maria Mircea, Mazène Hochane, Xueying Fan, Susana M. Chuva de Sousa Lopes, Diego Garlaschelli, Stefan Semrau
Journal: Genome biology (2022)

Abstract The ability to discover new cell phenotypes by unsupervised clustering of single-cell transcriptomes has revolutionized biology. Currently, there is no principled way to decide whether a cluster of cells contains meaningful subpopulations that should be further resolved. Here, we present phiclust (ϕ clust ), a clusterability measure derived from random matrix theory that can be used to identify cell clusters with non-random substructure, testably leading to the discovery of previously overlooked phenotypes.
SARS-CoV-2 RNA loads in Vietnamese children
Authors: Ton That Thanh, Nguyen Thi Thanh Nhan, Nguyen To Anh, Le Thanh Chung, Phan Thi Thuy Duyen, Le Thi Kim Chi, Nguyen Thi Hoai Thu, Pham Thi Hieu, Dinh Van Phuc, Pham Viet Son, Dang Quang Anh, Pham Thi Nam, Nguyen Tri Thuc, Nguyen Thi Hanh, Le Thi Thuy, Le Ly Thuy Tram, Le Kim Thanh, Nguyen Thi Han Ny, Le Nguyen Truc Nhu, Nguyen Van Vinh Chau, Guy Thwaites, Tran Tan Thanh, Le Van Tan
Journal: Journal of Infection (2022)
Deaths.
Journal: JAMA (1903)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Heart rate recovery after exercise testing and risk of coronary disease in the framingham heart study Ali Morshedi-Meibodi, Martin G. Larson, Daniel Levy, Christopher J. O'Donnell, Ramachandran S. Vasan. NHLBI's Framingham Heart Study, Framingham, MA, Boston University School Of Medicine, Boston, MA
Journal: Journal of the American College of Cardiology (2001)
Books Received
Authors: Giovanni A. Fava, Nicoletta Sonino, Anna Bartak, Marieke D. Spreeuwenberg, Helene Andrea, Lot Holleman, Piet Rijnierse, Bert V. Rossum, Elisabeth F.M. Hamers, Anke M.M.A. Meerman, Janneke Aerts, Jan J.V. Busschbach, Roel Verheul, Theo Stijnen, Paul M.G. Emmelkamp, Peter Herschbach, Petra Berg, Sabine Waadt, Gabriele Duran, Ursula Engst-Hastreiter, Gerhard Henrich, Katrin Book, Andreas Dinkel, B. Metternich, D. Kosch, L. Kriston, M. Härter, M. Hüll, Yutaka Matsuoka, Daisuke Nishi, Naohiro Yonemoto, Satomi Nakajima, Yoshiharu Kim, Manfred E. Beutel, Franz Bleichner, Friedrich von Heymann, Karin Tritt, Jochen Hardt, Eric Bui, Lionel Cailhol, Jacques Puel, Philippe Birmes, Laurent Schmitt, Anna Ogliari, Kristian Tambs, Jennifer R. Harris, Simona Scaini, Cesare Maffei, Ted Reichborn-Kjennerud, Marco Battaglia, Luigi Grassi, Silvana Sabato, Elena Rossi, Luciana Marmai, Bruno Biancosino
Journal: Psychotherapy and Psychosomatics (2009)